Monogram Orthopaedics (MGRM) to Release Earnings on Monday

Monogram Orthopaedics (NASDAQ:MGRM - Get Free Report) is anticipated to release its Q1 2025 earnings data before the market opens on Monday, May 12th. Analysts expect Monogram Orthopaedics to post earnings of ($0.10) per share for the quarter.

Monogram Orthopaedics (NASDAQ:MGRM - Get Free Report) last released its quarterly earnings data on Wednesday, March 12th. The company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.03. On average, analysts expect Monogram Orthopaedics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Monogram Orthopaedics Trading Up 0.3 %

Monogram Orthopaedics stock opened at $2.89 on Monday. Monogram Orthopaedics has a 1-year low of $1.84 and a 1-year high of $4.21. The firm has a market capitalization of $101.99 million, a PE ratio of -6.15 and a beta of 0.77. The firm's 50 day simple moving average is $2.69 and its 200 day simple moving average is $2.53.

Analyst Ratings Changes

Several research analysts have recently weighed in on MGRM shares. Roth Capital set a $5.40 price target on shares of Monogram Orthopaedics in a report on Tuesday, March 18th. Roth Mkm upped their target price on Monogram Orthopaedics from $4.00 to $5.40 and gave the stock a "buy" rating in a research note on Tuesday, March 18th.

About Monogram Orthopaedics

Monogram Orthopaedics, Inc focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.